Frazier Life Sciences Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Frazier Life Sciences Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$899M	Hold	7,679,684	–	–	19.58%	1
2026 Q1	$709M	Buy	7,679,684 +884,563	+13%	+$83.2M	18.25%	1
2025 Q4	$537M	Hold	6,795,121	–	–	14.42%	2
2025 Q3	$498M	Hold	6,795,121	–	–	14.93%	1
2025 Q2	$346M	Hold	6,795,121	–	–	13.83%	1
2025 Q1	$306M	Buy	6,795,121 +224,729	+3%	+$10.6M	13.99%	2
2024 Q4	$272M	Hold	6,570,392	–	–	11.28%	2
2024 Q3	$256M	Buy	6,570,392 +75,000	+1%	+$2.99M	10.27%	1
2024 Q2	$222M	Hold	6,495,392	–	–	10.39%	2
2024 Q1	$163M	Hold	6,495,392	–	–	6.88%	3
2023 Q4	$192M	Buy	6,495,392 +25,000	+0.4%	+$757K	10.25%	1
2023 Q3	$204M	Buy	6,470,392 +2,110,285	+48%	+$57.8M	13.58%	1
2023 Q2	$113M	Buy	4,360,107 +500,000	+13%	+$13.3M	6.74%	6
2023 Q1	$92.7M	Hold	3,860,107	–	–	6.71%	5
2022 Q4	$75.3M	Buy	3,860,107 +32,326	+0.8%	+$639K	4.68%	9
2022 Q3	$80.4M	Buy	3,827,781 +260,869	+7%	+$6.28M	6.19%	6
2022 Q2	$69.4M	Hold	3,566,912	–	–	6.55%	4
2022 Q1	$78.5M	Buy	+3,566,912	New	+$72.8M	6.69%	3

Other funds holding MIRM

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Frazier Life Sciences Management's MIRM Position: Q2 2026 in Review

Frazier Life Sciences Management held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2026 at 7,679,684 shares worth $899M. The position accounts for 19.58% of the portfolio, ranked #1.

Frazier Life Sciences Management first reported a position in MIRM in Q1 2022 and has held it in 18 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Frazier Life Sciences Management held 7,679,684 shares of Mirum Pharmaceuticals worth $899M as of Q2 2026.
Frazier Life Sciences Management left its Mirum Pharmaceuticals share count unchanged in Q2 2026.
Mirum Pharmaceuticals made up 19.58% of Frazier Life Sciences Management's portfolio in Q2 2026, its #1 holding.
Frazier Life Sciences Management first reported a position in Mirum Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.